Skip to content

Sublingual Immunotherapy Effect on Allergic Rhinitis

Comparison of the Effectiveness of Sublingual Immunotherapy(SLIT) with Routine Medical Treatment and it's Effect on Serum Level Changes of IL-25 and IL-33 in Patients with Allergic Rhinitis.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171105037262N1
Enrollment
90
Registered
2017-12-01
Start date
2017-12-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis. Allergic rhinitis due to pollen

Interventions

Intervention 1: Intervention group: Sublingual immunotherapy with drops manufactured by Wolwopharm in China with doses up to maintenance levels two drops of 1000 micrograms sublingual and for 6 months
Treatment - Drugs
Intervention group: Sublingual immunotherapy with drops manufactured by Wolwopharm in China with doses up to maintenance levels two drops of 1000 micrograms sublingual and for 6 months

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: Having Allergic Rhinitis Age over 12 years

Exclusion criteria

Exclusion criteria: Any Respiratory and non-respiratory inflammation such as infection; Recent Massive Surgery; Severe Pulmonary or Renal Disease; Alcohol Abuse; Sever Addiction; Uncontrolled Diabetes; Cancer; Autoimmune diseases

Design outcomes

Primary

MeasureTime frame
Interleukin 25. Timepoint: First and 24 weeks after intervention. Method of measurement: ELISA.;Interleukin 33. Timepoint: First and 24 weeks after intervention. Method of measurement: ELISA.

Secondary

MeasureTime frame
Disease severity. Timepoint: At the beginning of the study and 24 weeks after the intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Nikoueinejad

Bagheiat-allah University of Medical Sciences

hnikuinejad@yahoo.com+98 31 5554 2999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026